Petr Bely on the areas for development of innovative drug therapy in Russia
According to the Russian Ministry of Industry and Trade, the Industrial Development Fund has formed an investment portfolio of 50 billion rubles to support innovation in the Russian pharmaceutical industry. At SPIEF 2022, experts and government representatives presented current proposals for government support for the industry.
In an interview with RBC, the Chairman of the Board of Directors of Promomed Group Petr Bely outlined the areas for development of innovative drug therapy in Russia.
What are the main areas for development of innovative drug therapy in our country, and what specific steps are needed to implement this concept?
Petr Bely: Two and a half years ago, we faced the global threat of COVID-19, and I must say that the Russian government, the regulatory mechanism, and the willingness of the industry to provide a solution to combat the disease have yielded a tremendous result. We have a whole series of innovative drugs in various therapeutic groups. As a country, we are one of the champions in vaccine development. This showed Russia's excellent readiness to become a source of innovative solutions for the treatment of the most critical diseases that pose the greatest threat.
First. We need a very powerful system for protecting the intellectual property of Russian innovations. The system that would start with the first steps, from the inception an idea of a new drug to its successful presence on the market.
Second. We need to create a regulatory mechanism that would allow Russian developments in recognized therapeutic classes to enter the market quickly, but without reducing the volume of clinical trials or compromising the quality assessment.
Third. It is essential that markets for these drugs are created and that these drugs are absorbed by the health care system quickly.
In the coming months, we are opening a giant production of active pharmaceutical ingredients. It includes 150 items, seven workshops, three workshops are dedicated to oncological substances. But what matters is not our individual efforts, but the fact that so many people in our industry are doing the same. In a fairly short term, we will see a greater sufficiency of domestic substances for the production of our medicines.
What was the St. Petersburg International Economic Forum for you this year?
Petr Bely: We have signed a large comprehensive agreement with the Skolkovo Foundation. We also signed an agreement on cooperation and the opening of joint training and research activities in the field of pharmaceutical technologies with my home university, the Evdokimov Moscow State University of Medicine and Dentistry. We have signed a large agreement with the Mendeleev University of Chemical Technology. We have expanded the agreement with the Ogarev Mordovia State University.
Source: tv.rbc.ru
